Novartis AG vs Koninklijke Philips NV — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Koninklijke Philips NV trades at $26.77 (market cap $26.19B). The key difference: Novartis AG is far larger — about 11.1× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays the higher dividend (3.79%). Which is the better fit depends on your goals.
| NVS | PHG | |
|---|---|---|
Market Cap | $290.25B | $26.19B |
Sector | Health | Health |
52-Week High | $168.62 | $32.91 |
52-Week Low | $113.50 | $24.54 |
Enterprise Value | $330.27B | $32.46B |
Dividend Yield | 3.17% | 3.79% |
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →